Macias R I, El-Mir M Y, Monte M J, Serrano M A, Garcia M J, Marin J J
Departments of Physiology-Pharmacology, University of Salamanca, 37007-Salamanca, Spain.
J Control Release. 1999 Feb 1;57(2):161-9. doi: 10.1016/s0168-3659(98)00114-x.
The aim of this work was to investigate both the existence of enterohepatic circulation of cisplatin-cholylglycinate complex, Bamet-R2, and the relevance of biliary versus urinary excretion of this compound. Two experimental models were used: (i) intraluminal perfusion of 'in situ' ileum in anaesthetized rats bearing a biliary catheter that permitted bile sample collection and (ii) conscious rats in which a permanent intraarterial catheter had been implanted to carry out sequential blood sampling after intravenous (i.v.) or intragastric (i.g.) drug administration. Total platinum in serum, bile, ileum, liver, urine and feces was measured by flameless atomic absorption spectroscopy. Serum concentration versus time curves obtained after i.v. administration of 1 micromol Bamet-R2 or cisplatin revealed that the area under the curve was significantly higher for Bamet-R2 than for cisplatin (+48%). Non-ultrafiltrable platinum accounted for 54.8 and 48.4% of serum platinum 168 h after cisplatin and Bamet-R2 i.v. administration, respectively. When the animals received i.g. 1 micromol cisplatin or Bamet-R2, serum concentrations of total platinum were markedly higher (three-fold) after Bamet-R2 than after cisplatin administration. The area under the curve was, also in this case, significantly higher for Bamet-R2 than for cisplatin (+28%). This was in part due to the enhanced intestinal absorption of Bamet-R2, as confirmed in experiments on perfused rat ileum, where a markedly higher amount of the drug was found in ileum tissue and bile after perfusion with media containing Bamet-R2 as compared with experiments where cisplatin instead of Bamet-R2 was added to perfusion media. Moreover, after i.v. administration to conscious rats, excretion of Bamet-R2 by the kidney was three-fold lower than that of cisplatin, while elimination of the former compound into feces was four-fold higher than that of the latter. In summary, these results indicate that in addition to the previously reported cytostatic activity of Bamet-R2, this complex has interesting cholephilic characteristics typical of bile acids, such as low urinary excretion together with enhanced intestinal absorption and biliary secretion, probably endowed by the cholylglycyl moiety included in the Bamet-R2 molecule.
本研究旨在探究顺铂 - 甘氨胆酸复合物(Bamet - R2)肝肠循环的存在情况以及该化合物经胆汁排泄与经尿液排泄的相关性。采用了两种实验模型:(i)对带有胆管导管的麻醉大鼠的“原位”回肠进行腔内灌注,以便收集胆汁样本;(ii)对清醒大鼠植入永久性动脉导管,在静脉注射(i.v.)或胃内给药(i.g.)后进行连续采血。通过无火焰原子吸收光谱法测定血清、胆汁、回肠、肝脏、尿液和粪便中的总铂含量。静脉注射1微摩尔Bamet - R2或顺铂后获得的血清浓度 - 时间曲线显示,Bamet - R2的曲线下面积比顺铂显著更高(高48%)。静脉注射顺铂和Bamet - R2后168小时,血清中不可超滤的铂分别占血清铂的54.8%和48.4%。当动物接受胃内给予1微摩尔顺铂或Bamet - R2时,Bamet - R2给药后血清总铂浓度明显更高(高三倍)。在这种情况下,Bamet - R2的曲线下面积也比顺铂显著更高(高28%)。这部分归因于Bamet - R2肠道吸收增强,在灌注大鼠回肠的实验中得到证实,与在灌注培养基中添加顺铂而非Bamet - R2的实验相比,用含Bamet - R2的培养基灌注后,回肠组织和胆汁中发现的药物量明显更高。此外,对清醒大鼠静脉注射后,Bamet - R2经肾脏的排泄比顺铂低三倍,而该化合物经粪便的消除比顺铂高四倍。总之,这些结果表明,除了先前报道的Bamet - R2的细胞抑制活性外,该复合物具有胆汁酸典型的有趣的亲胆特性,如低尿排泄以及增强的肠道吸收和胆汁分泌,这可能是由Bamet - R2分子中包含的甘氨胆酰部分赋予的。